Search Results - "RUSTUM, Youcef"

A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity by Ling, Xiang, Cao, Shousong, Cheng, Qiuying, Keefe, James T, Rustum, Youcef M, Li, Fengzhi

“…Drug/radiation resistance to treatment and tumor relapse are major obstacles in identifying a cure for cancer. Development of novel agents that address these…”
Get full text

Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: preclinical and clinical development by Zakharia, Yousef, Bhattacharya, Arup, Rustum, Youcef M

“…Selenium (Se)-containing molecules exert antioxidant properties and modulate targets associated with tumor growth, metastasis, angiogenesis, and drug…”
Get full text

Potential Role of Selenium in the Treatment of Cancer and Viral Infections by Rataan, Aseel O, Geary, Sean M, Zakharia, Yousef, Rustum, Youcef M, Salem, Aliasger K

“…Selenium has been extensively evaluated clinically as a chemopreventive agent with variable results depending on the type and dose of selenium used. Selenium…”
Get full text

MicroRNA-627 Mediates the Epigenetic Mechanisms of Vitamin D to Suppress Proliferation of Human Colorectal Cancer Cells and Growth of Xenograft Tumors in Mice by Padi, Sathish K.R, Zhang, Qunshu, Rustum, Youcef M, Morrison, Carl, Guo, Bin

“…Background & Aims Vitamin D protects against colorectal cancer through unclear mechanisms. We investigated the effects of calcitriol (1α,25-dihydroxyvitamin D3…”
Get full text

Druggable Biomarkers Altered in Clear Cell Renal Cell Carcinoma: Strategy for the Development of Mechanism-Based Combination Therapy by Rustum, Youcef M, Reis, Ryan, Rustum, Tara M

“…Targeted therapeutics made significant advances in the treatment of patients with advanced clear cell renal cell carcinoma (ccRCC). Resistance and serious…”
Get full text

Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy by Rustum, Youcef M, Chintala, Sreenivasulu, Durrani, Farukh A, Bhattacharya, Arup

“…Durable response, inherent or acquired resistance, and dose-limiting toxicities continue to represent major barriers in the treatment of patients with advanced…”
Get full text

Enrico Mihich, MD: In Memoriam (1928-2016) by Foti, Margaret, Rustum, Youcef M

Get full text

Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition by Chintala, Sreenivasulu, Najrana, Tanbir, Toth, Karoly, Cao, Shousong, Durrani, Farukh A, Pili, Roberto, Rustum, Youcef M

“…Clear cell renal cell carcinoma (ccRCC) accounts for more than 80% of the cases of renal cell carcinoma. In ccRCC deactivation of Von-Hippel-Lindau (VHL) gene…”
Get full text

MicroRNA Expression in Clear Cell Renal Cell Carcinoma Cell Lines and Tumor Biopsies: Potential Therapeutic Targets by Swearson, Samuel, Rataan, Aseel O, Eliason, Steven, Amendt, Brad A, Zakharia, Yousef, Salem, Aliasger K, Ho, Thai, Rustum, Youcef M

“…This study was carried out to quantitate the expression levels of microRNA-17, -19a, -34a, -155, and -210 (miRs) expressed in nine clear cell renal cell…”
Get full text

Current Landscape and the Potential Role of Hypoxia-Inducible Factors and Selenium in Clear Cell Renal Cell Carcinoma Treatment by Garje, Rohan, An, Josiah J, Sanchez, Kevin, Greco, Austin, Stolwijk, Jeffrey, Devor, Eric, Rustum, Youcef, Zakharia, Yousef

“…In the last two decades, the discovery of various pathways involved in renal cell carcinoma (RCC) has led to the development of biologically-driven targeted…”
Get full text

Selective Modulation of the Therapeutic Efficacy of Anticancer Drugs by Selenium Containing Compounds against Human Tumor Xenografts by SHOUSONG CAO, DURRANI, Farukh A, RUSTUM, Youcef M

“…Purpose: Studies were carried out in athymic nude mice bearing human squamous cell carcinoma of the head and neck (FaDu and A253) and colon carcinoma (HCT-8…”
Get full text

Targeting the oncogenic protein beta-catenin to enhance chemotherapy outcome against solid human cancers by Saifo, Maher S, Rempinski, Jr, Donald R, Rustum, Youcef M, Azrak, Rami G

“…Beta-catenin is a multifunctional oncogenic protein that contributes fundamentally to cell development and biology. Elevation in expression and activity of…”
Get full text

Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines by HOLLER, Daniel G, CASSIDY, Jim, BERTINO, Joseph R, DOUILLARD, Jean-Yves, GUSTAVSSON, Bengt G, MILANO, Gerard, O'CONNELL, Michael, RUSTUM, Youcef, TABERNERO, Josep, GILBERG, Frank, SIRZEN, Florin, TWELVES, Chris, CLARKE, Stephen J, CUNNINGHAM, David, VAN CUTSEM, Eric, HOFF, Paulo M, ROTHENBERG, Mace L, SALTZ, Leonard B, SCHMOLL, Hans-Joachim, ALLEGRA, Carmen

“…We conducted a retrospective analysis of safety data from randomized, single-agent fluoropyrimidine clinical trials (bolus fluorouracil/leucovorin [FU/LV] and…”
Get full text

Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts by Cao, Shousong, Durrani, Farukh A, Toth, Karoly, Rustum, Youcef M, Seshadri, Mukund

“…Summary Combining antiangiogenic agents with traditional cytotoxic chemotherapy offers the potential to target both vascular and cellular components of a…”
Get full text

Tumor Vascular Maturation and Improved Drug Delivery Induced by Methylselenocysteine Leads to Therapeutic Synergy with Anticancer Drugs by BHATTACHARYA, Arup, SESHADRI, Mukund, OVEN, Steven D, TOTH, Karoly, VAUGHAN, Mary M, RUSTUM, Youcef M

“…Purpose: Our previously reported therapeutic synergy between naturally occurring seleno-amino acid methylselenocysteine (MSC) and anticancer drugs could not be…”
Get full text

Constitutive expression of HIF-α plays a major role in generation of clear-cell phenotype in human primary and metastatic renal carcinoma by Tóth, Károly, Chintala, Sreenivasulu, Rustum, Youcef M

“…The extensive lipid accumulation occurring in clear-cell renal cell carcinoma (ccRCC) results in a clear-cell cytoplasm. Hypoxia-inducible factor α (HIF-α) is…”
Get full text

Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1α by Chintala, Sreenivasulu, Tόth, Károly, Cao, Shousong, Durrani, Farukh A, Vaughan, Mary M, Jensen, Randy L, Rustum, Youcef M

“…Purpose Hypoxic tumor cells overexpressing hypoxia-inducible factor 1alpha (HIF-1α) are generally resistant to chemo/radiotherapy. We have reported that…”
Get full text

Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview by Vanhoefer, U, Harstrick, A, Achterrath, W, Cao, S, Seeber, S, Rustum, Y M

“…For more than three decades, the therapeutic options for patients with advanced colorectal cancer have almost exclusively been based on fluoropyrimidines. With…”
Get full text

A Phase I, Pharmacokinetic and Pharmacodynamic Study on Vorinostat in Combination with 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Refractory Colorectal Cancer by FAKIH, Marwan G, PENDYALA, Lakshmi, EGORIN, Merrill J, FETTERLY, Gerald, TOTH, Karoli, ZWIEBEL, James A, ESPINOZA-DELGADO, Igor, LITWIN, Alan, RUSTUM, Youcef M, ROSS, Mary Ellen, HOLLERAN, Julianne L

“…Purpose: We conducted a phase I study to determine the maximum tolerated dose of vorinostat in combination with fixed doses of 5-fluorouracil (FU), leucovorin,…”
Get full text

Thymidylate synthase: a critical target in cancer therapy? by Rustum, Youcef M

“…For the last four decades, synthesis and testing of potentially active drugs (e.g., antimetabolites) have focused on structural modification of existing…”
Get full text